NDAINTRAVENOUSSOLUTION
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CERIANNA (fluoroestradiol f 18) by GE HealthCare is positron emitting activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 2020.
Drug data last refreshed 13h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERIANNA (Fluoroestradiol F-18) is a positron-emitting radioactive diagnostic agent administered intravenously as a solution. It functions as a radiopharmaceutical for diagnostic imaging applications, enabling visualization of estrogen receptor activity in patients. The drug targets nuclear medicine and oncology imaging markets where hormone receptor status assessment is clinically relevant.
Peak
Product is in peak revenue phase post-2020 launch with minimal data disclosure, suggesting established utilization and stable team investment by GE HealthCare.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Why This Matters for Your Career
Worked on CERIANNA at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.